|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9201
|
|
pubmed:dateCreated |
2000-2-15
|
|
pubmed:abstractText |
Resistance to cheap effective antimalarial drugs, especially to pyrimethaminesulphadoxine (Fansidar), is likely to have a striking impact on childhood mortality in sub-Sharan Africa. The use of artesunate (artesunic acid) [corrected] in combination with pyrimethamine-sulphadoxine may delay or prevent resistance. We investigated the efficacy, safety, and tolerability of this combined treatment.
|
|
pubmed:commentsCorrections |
|
|
pubmed:keyword |
http://linkedlifedata.com/resource/pubmed/keyword/Africa,
http://linkedlifedata.com/resource/pubmed/keyword/Africa South Of The Sahara,
http://linkedlifedata.com/resource/pubmed/keyword/Age Factors,
http://linkedlifedata.com/resource/pubmed/keyword/CHILD,
http://linkedlifedata.com/resource/pubmed/keyword/DRUGS,
http://linkedlifedata.com/resource/pubmed/keyword/Demographic Factors,
http://linkedlifedata.com/resource/pubmed/keyword/Developing Countries,
http://linkedlifedata.com/resource/pubmed/keyword/Diseases,
http://linkedlifedata.com/resource/pubmed/keyword/Double-blind Studies,
http://linkedlifedata.com/resource/pubmed/keyword/English Speaking Africa,
http://linkedlifedata.com/resource/pubmed/keyword/Gambia,
http://linkedlifedata.com/resource/pubmed/keyword/MALARIA,
http://linkedlifedata.com/resource/pubmed/keyword/PARASITIC DISEASES,
http://linkedlifedata.com/resource/pubmed/keyword/Population,
http://linkedlifedata.com/resource/pubmed/keyword/Population Characteristics,
http://linkedlifedata.com/resource/pubmed/keyword/Research Methodology,
http://linkedlifedata.com/resource/pubmed/keyword/Research Report,
http://linkedlifedata.com/resource/pubmed/keyword/Studies,
http://linkedlifedata.com/resource/pubmed/keyword/Treatment,
http://linkedlifedata.com/resource/pubmed/keyword/Western Africa,
http://linkedlifedata.com/resource/pubmed/keyword/Youth
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
pubmed-author:AllouecheAA,
pubmed-author:AnyalebechiCC,
pubmed-author:BojangKK,
pubmed-author:ColemanRR,
pubmed-author:DohertyTT,
pubmed-author:DuraisinghMM,
pubmed-author:GoslingRR,
pubmed-author:GreenwoodBB,
pubmed-author:McAdamKK,
pubmed-author:MilliganPP,
pubmed-author:OlliaroPP,
pubmed-author:PinderMM,
pubmed-author:SadiqAA,
pubmed-author:TargettGG,
pubmed-author:UdeJ IJI,
pubmed-author:WalravenGG,
pubmed-author:WarhurstDD,
pubmed-author:von SeidleinLL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
29
|
|
pubmed:volume |
355
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
352-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:otherAbstract |
PIP: This double-blind, randomized, controlled study investigated the efficacy, safety and tolerability of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria among Gambian children. Combined use of artesunate and pyrimethamine-sulphadoxine was hypothesized to delay or prevent resistance, which proved to be effective in reducing childhood mortality in sub-Saharan Africa. A total of 600 children with acute uncomplicated Plasmodium falciparum malaria, 6 months to 10 years old, were randomly administered pyrimethamine-sulphadoxine (25 mg/500 mg) with placebo, 4 mg/kg body weight pyrimethamine-sulphadoxine plus 1 dose of artesunate, or pyrimethamine-sulphadoxine plus 4 mg/kg body weight artesunate for 3 days. Results indicate that combined treatment was well tolerated. On day 1, 178 of 381 children treated with artesunate were still parasitemic compared with 157 of 195 children in the pyrimethamine-sulphadoxine group. On the other hand, failure rates on day 14 were 3.1% in the pyrimethamine-sulphadoxine group and 3.7% in the 1-dose artesunate group and 1.6% in the 3-dose group. Insignificant differences were found among children administered 1-dose and 3-dose artesunate, and were found less likely to be gametocytemic after treatment. In conclusion, this study confirms the safety and efficacy of a combined treatment, which eventually results in lower gametocyte rates and lower transmission rates.
|
|
pubmed:meshHeading |
pubmed-meshheading:10665554-Animals,
pubmed-meshheading:10665554-Antimalarials,
pubmed-meshheading:10665554-Artemisinins,
pubmed-meshheading:10665554-Child,
pubmed-meshheading:10665554-Child, Preschool,
pubmed-meshheading:10665554-Double-Blind Method,
pubmed-meshheading:10665554-Drug Combinations,
pubmed-meshheading:10665554-Drug Therapy, Combination,
pubmed-meshheading:10665554-Female,
pubmed-meshheading:10665554-Gambia,
pubmed-meshheading:10665554-Humans,
pubmed-meshheading:10665554-Infant,
pubmed-meshheading:10665554-Malaria, Falciparum,
pubmed-meshheading:10665554-Male,
pubmed-meshheading:10665554-Parasitemia,
pubmed-meshheading:10665554-Plasmodium falciparum,
pubmed-meshheading:10665554-Pyrimethamine,
pubmed-meshheading:10665554-Sesquiterpenes,
pubmed-meshheading:10665554-Sulfadoxine
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial.
|
|
pubmed:affiliation |
Farafenni Field Station, Medical Research Council Laboratories, The Gambia. lseidlein@mrc.gm
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
